Skip to content

Balanced Placebo Design With Varenicline: Pharmacological and Expectancy Effects on Medication Adherence

Varenicline Pharmacological and Expectancy Effects on Medication Adherence (Balanced Placebo Design With Varenicline: Pharmacological and Expectancy Effects on Medication Adherence)

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03538808
Enrollment
80
Registered
2018-05-29
Start date
2018-11-06
Completion date
2019-10-29
Last updated
2020-12-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Medication Adherence

Brief summary

The current study will use the double-blind balanced placebo design to examine differences between expectancies versus the pharmacological effects of varenicline medication administered for two weeks to cigarette smokers. The double-blind balanced placebo design includes medication administration (active medication v. placebo) and medication information (told truth v. deception) resulting in four groups of smokers: (1) told therapeutic dose (TD) medication + received TD medication; (2) told TD medication + received placebo; (3) told low dose (LD) medication+ received TD dose medication; (4) told LD medication + received placebo. Ecological momentary assessments (EMA) in the form of Daily Dairies delivered via smartphone will assess real-time side effects, withdrawal symptoms, cigarettes smoked, medication use, and reasons for medication non-adherence.

Detailed description

The current proposal will utilize the double-blind balanced placebo design to differentiate expectancies versus pharmacologic mechanisms of varenicline administered to varenicline naïve smokers seeking treatment (N = 80) for two-weeks. Race block randomization (controlling for baseline expectancies) will be used to randomize participants. The double-blind balanced placebo design includes a cross-balanced medication administration (active medication v. placebo) and instructional set (told truth v. deception) resulting in four groups of smokers seeking treatment (n = 20 for each): (1) told therapeutic dose (TD) medication + received TD medication; (2) told TD medication + received placebo; (3) told low dose (LD) medication+ received TD dose medication; (4) told LD medication + received placebo. Participants will be told they received low dose (rather than placebo) due to concerns that participants will not take a medication that they believe to be a placebo. Ecological momentary assessments (EMA) in the form of Daily Dairies delivered via smartphone will assess real-time side effects, withdrawal symptoms, cigarettes smoked, medication use, and reasons for medication non-adherence. The current proposal will test the following specific aims: Specific Aim 1: Examine the main effects of instructional set and pharmacology. Hypothesis 1: Main effects for TD instructional set and active medication administration will result in reduced medication adherence compared with LD instructional set and placebo medication. Specific Aim 2: Examine the interaction between instructional set and pharmacology. Hypothesis 2: There will be a synergistic (i.e., non-additive) effect between instructional set and pharmacology. Specifically, those assigned to the TD instructional set and active medication group will result in a 50% discontinuation compared to a 20% discontinuation in the TD instructional set and placebo medication group. Exploratory Aim: Evaluate moderators of pharmacology and expectancy effects on medication adherence. First, we will conduct exploratory examination of baseline medication expectancies moderating the relationship between pharmacology and medication adherence. Second, we will conduct an exploratory evaluation of potential moderators (e.g., gender and race) of pharmacology and baseline medication expectancy.

Interventions

DRUGVarenicline

Participants will be provided varenicline medication

OTHERPlacebo

Participants will be provided placebo medication

Sponsors

University of Alabama at Birmingham
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
FACTORIAL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)

Masking description

double-blind

Intervention model description

Balanced placebo design

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* 18 years or older * Smoking at least 5 cigarettes per day (cpd) for the past year * A carbon monoxide (CO) \>10ppm * English speaking * Must own a cellphone with SMS text capacity with Internet access OR daily use of email * Must be varenicline naïve * Express a desire to quit smoking

Exclusion criteria

* Living in a restricted environment (e.g., prison or jail facility, etc.) * Pregnant or nursing * Currently enrolled in a smoking cessation treatment program, using NRT products, or prescribed bupropion or varenicline * Known allergy to varenicline * History of kidney disease, dialysis or known kidney impairment * Cognitive impairment or unstable psychiatric condition that interferes with the informed consent process (individuals stable on psychiatric medications will be included) * Daily or exclusive use of other tobacco products * Current suicidal or homicidal ideation or a suicidal attempt within the past 12 months * History of stroke, heart attack, or seizures

Design outcomes

Primary

MeasureTime frameDescription
Medication AdherenceDays 1 - 13Self-reported medication adherence measured through a single item assessing medication compliance. The item is answered as yes (scored as 1) or no (scored as 0). This measure combines all responses from Day 1 through Day 13 of this study to provide a total measure of medication adherence ranging from 0% (missed all doses) to 100% (took every dose as prescribed). Higher scores indicate better outcomes (i.e., better adherence to medication).

Secondary

MeasureTime frameDescription
Medication ExpectanciesBaseline and Day 14Medication expectancies will be measured through the Beliefs and Attitudes about Varenicline (BAV) scale which is a 6-item questionnaire adapted to assess varenicline expectancies. This measure is rated on a scale from 1 (not at all) to 5 (extremely). The measure has a minimum score of 6 and a maximum score of 30. Higher scores indicating better outcomes (i.e., stronger positive beliefs about using varenicline).

Other

MeasureTime frameDescription
Side EffectsDay 14A 30-item self-report measure of the presence (or not) of symptoms commonly associated with varenicline side effects and nicotine withdrawal. Items are rated as No (scored as 0) or Yes (scored as 1). A total score was calculated to reflect the total number of reported side effects. This measure has a minimum score of 0 and a maximum score of 30. Higher scores indicate worse outcomes (i.e., greater frequency of experienced side effects).

Countries

United States

Participant flow

Pre-assignment details

None, all participants that were enrolled in the study were randomized into one of the four conditions.

Participants by arm

ArmCount
Therapeutic Dose/Varenicline
Participants were told they were provided with a therapeutic dose of varenicline and they received varenicline medication.
20
Therapeutic Dose/Placebo
Participants were told they received a therapeutic dose varenicline, but they received a placebo.
20
Low Dose/Varenicline
Participants were told they received a very low dose varenicline, but they received a therapeutic dose varenicline.
20
Low Dose/Placebo
Participants were told they received a very low dose varenicline, but they received a placebo.
20
Total80

Baseline characteristics

CharacteristicTherapeutic Dose/VareniclineTotalLow Dose/PlaceboLow Dose/VareniclineTherapeutic Dose/Placebo
Age, Continuous49.15 years
STANDARD_DEVIATION 2.59
46.86 years
STANDARD_DEVIATION 11.51
45.30 years
STANDARD_DEVIATION 2.59
45.00 years
STANDARD_DEVIATION 2.59
48.00 years
STANDARD_DEVIATION 2.59
Ethnicity (NIH/OMB)
Hispanic or Latino
0 Participants2 Participants1 Participants1 Participants0 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
20 Participants78 Participants19 Participants19 Participants20 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
0 Participants0 Participants0 Participants0 Participants0 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants0 Participants0 Participants0 Participants0 Participants
Race (NIH/OMB)
Asian
0 Participants0 Participants0 Participants0 Participants0 Participants
Race (NIH/OMB)
Black or African American
10 Participants40 Participants10 Participants10 Participants10 Participants
Race (NIH/OMB)
More than one race
1 Participants1 Participants0 Participants0 Participants0 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants0 Participants0 Participants0 Participants0 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants0 Participants0 Participants0 Participants0 Participants
Race (NIH/OMB)
White
9 Participants39 Participants10 Participants10 Participants10 Participants
Sex: Female, Male
Female
5 Participants31 Participants13 Participants5 Participants8 Participants
Sex: Female, Male
Male
15 Participants49 Participants7 Participants15 Participants12 Participants
Stanford Expectations of Treatment Scale: Negative Subscale3.42 units on a scale
STANDARD_DEVIATION 0.34
3.33 units on a scale
STANDARD_DEVIATION 1.48
3.3 units on a scale
STANDARD_DEVIATION 0.34
3.4 units on a scale
STANDARD_DEVIATION 0.34
3.2 units on a scale
STANDARD_DEVIATION 0.34

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
EG002
affected / at risk
EG003
affected / at risk
deaths
Total, all-cause mortality
0 / 200 / 200 / 200 / 20
other
Total, other adverse events
1 / 201 / 201 / 201 / 20
serious
Total, serious adverse events
0 / 200 / 200 / 200 / 20

Outcome results

Primary

Medication Adherence

Self-reported medication adherence measured through a single item assessing medication compliance. The item is answered as yes (scored as 1) or no (scored as 0). This measure combines all responses from Day 1 through Day 13 of this study to provide a total measure of medication adherence ranging from 0% (missed all doses) to 100% (took every dose as prescribed). Higher scores indicate better outcomes (i.e., better adherence to medication).

Time frame: Days 1 - 13

ArmMeasureValue (NUMBER)
Therapeutic Dose/VareniclineMedication Adherence85.36 Percentage
Therapeutic Dose/PlaceboMedication Adherence86.79 Percentage
Low Dose/VareniclineMedication Adherence81.93 Percentage
Low Dose/PlaceboMedication Adherence86.09 Percentage
Secondary

Medication Expectancies

Medication expectancies will be measured through the Beliefs and Attitudes about Varenicline (BAV) scale which is a 6-item questionnaire adapted to assess varenicline expectancies. This measure is rated on a scale from 1 (not at all) to 5 (extremely). The measure has a minimum score of 6 and a maximum score of 30. Higher scores indicating better outcomes (i.e., stronger positive beliefs about using varenicline).

Time frame: Baseline and Day 14

ArmMeasureValue (MEAN)
Therapeutic Dose/VareniclineMedication Expectancies3.56 units on a scale
Therapeutic Dose/PlaceboMedication Expectancies3.65 units on a scale
Low Dose/VareniclineMedication Expectancies3.50 units on a scale
Low Dose/PlaceboMedication Expectancies3.44 units on a scale
Other Pre-specified

Side Effects

A 30-item self-report measure of the presence (or not) of symptoms commonly associated with varenicline side effects and nicotine withdrawal. Items are rated as No (scored as 0) or Yes (scored as 1). A total score was calculated to reflect the total number of reported side effects. This measure has a minimum score of 0 and a maximum score of 30. Higher scores indicate worse outcomes (i.e., greater frequency of experienced side effects).

Time frame: Day 14

ArmMeasureValue (MEAN)Dispersion
Therapeutic Dose/VareniclineSide Effects1.50 SymptomsStandard Error 0.57
Therapeutic Dose/PlaceboSide Effects3.40 SymptomsStandard Error 0.54
Low Dose/VareniclineSide Effects2.00 SymptomsStandard Error 0.61
Low Dose/PlaceboSide Effects1.89 SymptomsStandard Error 0.57

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026